Landos Biopharma Inc expected to post a loss of 19 cents a share - Earnings Preview

Landos Biopharma

20/03/2023 11:10

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on March 22
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Landos Biopharma
Inc is
for a loss of 19 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $2​, above​ its last closing price of $0.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.28       -0.28      -0.20     Beat    29.4
 Jun. 30 2022  -0.38       -0.36      -0.28     Beat    23.3
 Mar. 31 2022  -0.31       -0.35      -0.37     Missed  -6.7​
 Dec. 31 2021              -0.33                        
 ​​Sep.        -0.44       -0.44      -0.32     Beat    27
 30 2021                                                
 Jun. 30 2021  0.04        -0.14      0.12      Beat    185.7​
 Mar. 31 2021  -0.39       -0.37      -0.38     Missed  -1.3
 Dec. 31 2020  -0.69       -0.69      -0.91     Missed  -32.5
 This summary was machine generated March 20 at 11:10 GMT.  All
figures in US dollars  unless otherwise stated